Inviragen is focused on developing life-saving vaccines to protect against emerging infectious diseases worldwide.

Inviragen's lead product is a vaccine to protect against dengue fever, a disease that threatens 3.6 billion people across the globe. Clinical trials of our dengue vaccine are anticipated to begin in 2Q2010. 

Inviragen’s vaccines to protect against hand, foot and mouth disease and Japanese encephalitis also are progressing towards clinical trials.  Both of these diseases affect millions of children in Asia.  Vaccines in earlier preclinical research stages include a chikungunya vaccine, a low-cost human papilloma virus vaccine, a vaccine to protect against new forms of influenza, a combination plague/smallpox vaccine and a West Nile vaccine.